US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
New York-based Mind Medicine, a company developing MM120, a form of LSD (lysergide d-tartrate), for mental health conditions, has announced the appointment of Gregg Pratt, as chief regulatory and quality assurance officer. 19 November 2024
Belgian biotech start-up ExeVir Bio says it has appointed Michael Garrett as its new chief executive (CEO), effective 1 December 2024. 18 November 2024
ALX Oncology Holdings, a Californian immuno-oncology company, has announced the appointment of Alan Sandler as chief medical officer (CMO). 14 November 2024
US ophthalmology specialist Ocular Therapeutix announced that Namrata Saroj has joined the Company on a full-time basis as chief business officer (CBO). Dr Saroj previously served as development strategy consultant to Ocular since February 2024. 14 November 2024
VarmX, a Dutch biotech developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders, has appointed industry veteran John Glasspool (pictured, above) as chief executive. 12 November 2024
French biotech DiogenX, which is focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of Dr Klara Owen as chief medical officer. 12 November 2024
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Memo Therapeutics, a privately-held Swiss biotech company translating unique responses into superior medicines to treat viral infections and cancer, has appointed a new chief development officer (CDO). 4 November 2024
Netherlands-based Tessellate BIO, a pre-clinical stage biotech with a focus on novel synthetic lethality approaches, today announced the appointment of Dr Lara Boyd as chief business officer. 4 November 2024
Fennec Pharmaceuticals has announced the addition of three new executives to bolster its leadership team as the company prepares for expanded commercial operations. 28 October 2024
US healthcare giant Johnson & Johnson revealed yesterday that long-serving Alex Gorsky, who has held the posts of chairman and chief executive since 2012, will serve as executive chairman of the group. 20 August 2021
US pharma major Eli Lilly has announced executive leadership changes and the creation of neuroscience and immunology business units. Effective September 5, Lilly Bio-Medicines will split into two business units: Lilly Neuroscience and Lilly Immunology. 18 August 2021
US privately-held biotech HiberCell today announced the acquisition of Genuity Science, a life science technology company – previously known as WuXi NextCODE and with Chinese backing - that provides world-leading genomics and multi-omic analytics bolstered by an advanced artificial intelligence (AI) and machine learning (ML) platform to illuminate the underlying cause of cancer and other diseases. 17 August 2021
USA-based cancer specialist Epizyme today announced a collaboration with Chinese biotech Hutchmed to research, develop, manufacture and commercialize Tazverik (tazemetostat) in Greater China, including mainland China, Hong Kong, Macau and Taiwan (the Territory). 9 August 2021
BlueRock Therapeutics, a clinical stage biopharmaceutical company, a wholly-owned clinical-stage subsidiary of Germany’s Bayer, has revealed changes in its top executive team. 26 July 2021
GlaxoSmithKline has confirmed the current head of its consumer health joint venture (JV) will continue as chief executive once the unit is spun out into a standalone business. 23 July 2021
US oncology-focussed biotech Arcus Biosciences today announced that Dr Bill Grossman will transition out of his role as chief medical officer at Arcus and into a role at Gilead Sciences as senior vice president of oncology clinical research to oversee Gilead’s clinical-stage oncology portfolio. 20 July 2021
Italian drugmaker Recordati’s board of directors has approved the appointment of Rob Koremans as chief executive effective December 1, 2021. 16 July 2021
Belgian cell therapy company Bone Therapeutics, which is addressing unmet medical needs in orthopedics and other diseases, has appointed Anne Leselbaum as chief medical officer (CMO), effective August 23, 2021. 12 July 2021
Boston, USA-based next-generation oncology company Scorpion Therapeutics says that Dr Axel Hoos will join the company as its new chief executive, effective August 2021. 8 July 2021
Dutch specialty pharma company Pharming Group said today it has appointed Anurag Relan as chief medical officer (CMO), effective immediately, and Robert Friesen as chief scientific officer, effective from August 1, 2021. 18 June 2021
Germany’s Merck KGaA is further pushing its science and technology based strategic growth trajectory with two appointments to key senior leadership positions on Group level. In both cases internal candidates will be promoted which underlines the high quality of Merck’s top talent pipeline. 1 June 2021